Trends in E-Cigarette Use Among Various Subgroups

Gunasekaran, Kulothungan; Rahi, Mandeep Singh; Rajasurya, Venkat; Wolff, Armand

doi:10.1016/j.amjmed.2020.04.018

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Baseline symptoms like dyspnea severity, exertional ability, cough frequency, sputum volume, and purulence should also be established. In addition to a detailed smoking history, marijuana use and vaping usage should be documented as well [18,19]. Lastly, if not already achieved, smoking cessation is essential to prevent further decline in lung function, and various pharmacological and non-pharmacological approaches are available to accomplish this [20].…”

Section: Initial Assessment Of Patients With Refractory Copd 21 Evalu...mentioning

confidence: 99%

Management of Refractory Chronic Obstructive Pulmonary Disease: A Review

Rahi,

Mudgal,

Asokar

et al. 2024

Life

Self Cite

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a common condition with an estimated prevalence of 12% in adults over the age of 30 years worldwide. COPD is a leading cause of morbidity and mortality globally, with a substantial economic and social burden. There are an estimated 3 million deaths annually due to COPD. However, most of the patients with COPD respond to routine interventions like bronchodilator therapy, assessing supplemental oxygen needs, smoking cessation, vaccinations, and pulmonary rehabilitation. There is a significant number of patients who unfortunately progress to have persistent symptoms despite these interventions. Refractory COPD is not yet formally defined. Patients with severe persistent symptoms or exacerbations despite appropriate care can be considered to have refractory COPD. Managing refractory COPD needs a multidimensional approach. In this review article, we will discuss essential interventions like ensuring adequate inhaler techniques, exploring the need for non-invasive ventilatory support, use of chronic antibiotics and phosphodiesterase inhibitors to advanced therapies like bronchoscopic lung volume reduction surgery, and the upcoming role of anti-IL5 agents in managing patients with refractory COPD. We will also discuss non-pharmacologic interventions like psycho-social support and nutritional support. We will conclude by discussing the palliative care aspect of managing patients with refractory COPD. Through this review article, we aim to better the approach to managing patients with refractory COPD and discuss new upcoming therapies.

show abstract

Section: Initial Assessment Of Patients With Refractory Copd 21 Evalu...mentioning

confidence: 99%

Management of Refractory Chronic Obstructive Pulmonary Disease: A Review

Rahi,

Mudgal,

Asokar

et al. 2024

Life

Self Cite

View full text Add to dashboard Cite

show abstract

“…During the initial study time period, there might be social desirability bias in disclosing cannabis use. 52,53 Another significant limitation is that this study is constrained by data elements provided by HCUP-NIS. It lacks data on readmissions and patient-level clinical information such as the body mass index, the cause of death, quantification, and route of cannabis or cigarette smoking.…”

Section: Study Limitationsmentioning

confidence: 99%

Trends in Prevalence and Outcomes of Cannabis Use Among Chronic Obstructive Pulmonary Disease Hospitalizations: A Nationwide Population-Based Study 2005–2014

Gunasekaran

Voruganti

Rahi

et al. 2021

Cannabis and Cannabinoid Research

Self Cite

View full text Add to dashboard Cite

Background: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of mortality in the United States. Due to the ongoing legalization of cannabis, its acceptance, availability, and use in the in-patient population are on the rise. In this retrospective study, we investigated the association of cannabis use with important outcomes in COPD hospitalizations. Methods: The National Inpatient Sample (NIS) data were analyzed from 2005 to 2014. The primary outcome of interest was the trends and outcomes of cannabis use among COPD hospitalizations, including in-hospital mortality, pneumonia, sepsis, and respiratory failure. Results: We identified 6,073,862 hospitalizations, 18 years of age or older, with COPD using hospital discharge codes. Of these, 6,049,316 (99.6%) were without cannabis use, and 24,546 (0.4%) were admitted with cannabis use. The majority of COPD hospitalizations with cannabis use were aged 50-64 (60%). Cannabis use was associated with lower odds of in-hospital mortality (odds ratio [OR] 0.624 [95% confidence interval (CI) 0.407-0.958]; p = 0.0309) and pneumonia (OR 0.882 [95% CI 0.806-0.964]; p = 0.0059) among COPD hospitalizations. Cannabis use also had lower odds of sepsis (OR 0.749 [95% CI 0.523-1.071]; p = 0.1127) and acute respiratory failure (OR 0.995 [95% CI 0.877-1.13]; p = 0.9411), but it was not statistically significant. Conclusions: Among hospitalized patients with a diagnosis of COPD, cannabis users had statistically significant lower odds of in-hospital mortality and pneumonia compared to noncannabis users. The association between cannabis use and these favorable outcomes deserves further study to understand the interaction between cannabis use and COPD.

show abstract

Trends in E-Cigarette Use Among Various Subgroups

Cited by 2 publications

References 5 publications

Management of Refractory Chronic Obstructive Pulmonary Disease: A Review

Management of Refractory Chronic Obstructive Pulmonary Disease: A Review

Trends in Prevalence and Outcomes of Cannabis Use Among Chronic Obstructive Pulmonary Disease Hospitalizations: A Nationwide Population-Based Study 2005–2014

Contact Info

Product

Resources

About